



((R)-PCV-TP), or a pharmaceutically acceptable salt thereof.

Claim 9 (amended). The compound according to Claim 5 wherein the bioprecursor [h] is a derivative of (R)-PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Please add the following claims:

~~Claim 15. The method according to Claim 1 wherein (R)-PCV-TP is in the form of a bioprecursor, which is a derivative of (R)-PCV-MP.~~

~~Claim 16. The method according to Claim 15 wherein the bioprecursor is a PL-ASOR derivative.~~

Claim 17. The method according to Claim 7 wherein the bioprecursor is a A phospholipid derivative.

Claim 18. The method according to Claim 7 wherein the bioprecursor is a (R)-MP Bis(POM) derivative.

Claim 19. The method according to Claim 7 wherein the bioprecursor is a (R)-MP diphenyl ester derivative.

Claim 20. The method according to Claim 7 wherein the bioprecursor is a dimyristoylglycerol diphosphate derivative.